Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9944
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJones, Daryl Aen
dc.contributor.authorStory, David Aen
dc.date.accessioned2015-05-15T23:14:10Z
dc.date.available2015-05-15T23:14:10Z
dc.date.issued2005-04-01en
dc.identifier.citationAnaesthesia and Intensive Care; 33(2): 181-7en
dc.identifier.govdoc15960399en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/9944en
dc.description.abstractSerotonin syndrome results from excessive activation of serotonin (5-hydroxytryptamine; 5-HT) receptors in the nervous system, on the surface of platelets, and on the vascular endothelium. The clinical manifestations are a triad of altered conscious state, autonomic dysfunction, and neuromuscular excitability. Clinical diagnostic criteria remain poorly defined and unvalidated, and there are no available investigations to confirm the diagnosis. The syndrome is caused by the administration of one or more drugs possessing serotonergic activity. Severe forms of the syndrome usually result from overdose, but can be induced by monotherapy. The exact incidence of serotonin syndrome remains unknown, but is likely to be increasing due to increased prescription of selective serotonin reuptake inhibitor antidepressants and tramadol, as well as recreational use of amphetamine-like substances. Serotonin syndrome may complicate the administration of drugs frequently used in anaesthetic practice, including pethidine and tramadol. Although the majority of cases improve with symptomatic and supportive care, severe cases need intensive care and frequently require mechanical ventilation. Neuromuscular excitability is likely to be the cause of rhabdomyolysis seen in severe cases and should be treated with benzodiazepines and muscle relaxants. Supportive therapies are required to treat hyperthermia and autonomic dysfunction. Cyproheptadine is the most commonly administered serotonergic antagonist, but is unavailable in parenteral form.en
dc.language.isoenen
dc.subject.otherAnalgesics, Opioid.adverse effectsen
dc.subject.otherAnesthesiologyen
dc.subject.otherHumansen
dc.subject.otherSerotonin.biosynthesis.physiologyen
dc.subject.otherSerotonin Syndrome.chemically induced.diagnosis.physiopathologyen
dc.subject.otherTramadol.adverse effectsen
dc.titleSerotonin syndrome and the anaesthetist.en
dc.typeJournal Articleen
dc.identifier.journaltitleAnaesthesia and Intensive Careen
dc.identifier.affiliationDepartment of Anaesthesia, Austin Hospital, Heidelberg, Victoria.en
dc.description.pages181-7en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/15960399en
dc.type.austinJournal Articleen
local.name.researcherJones, Daryl A
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptIntensive Care-
crisitem.author.deptAnaesthesia-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

14
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.